KNEE OSTEOARTHRITIS AND METABOLIC SYNDROME: NEW APPROACHES TO THERAPY

Objective: to investigate the effect of diacerein (Diaflex) on some components of metabolic syndrome (MS) in patients with knee osteoarthritis (OA).

Subjects and methods. The multicenter open-label prospective study covered 55 patients aged 45 to 74 years with Kellgren–Lawrence Stage II–III knee OA and MS, with a pain intensity of >40 mm on a visual analogue scale, and with a disease duration of 1 to 30 years. The therapy duration was 6 months: Diaflex 50 mg/day for one month, then 50 mg twice daily for 5 months; the patients were followed up for the succeeding 3 months. During each visit, the efficiency and safety of treatment were evaluated; moreover, blood biochemical values were taken into account at the beginning and at the end of therapy.

Results and discussion. There was a statistically significant improvement in WOMAC index (all its components and total value) and quality of life using EQ-5D in the first month of therapy and throughout the follow-up. Analysis based on the OMERACT-OARSI criteria indicated high treatment response rates in 92.5% of the patients at the end of therapy and in 92.2% three months after its completion. The body mass index and levels of low-density lipoproteins, triglycerides, glucose, and uric acid significantly decreased during treatment. Adverse events were detected in a small number (5.5%) of cases.

Conclusion. Diaflex is an effective and safe drug in the treatment of knee OA in patients with MS. During therapy, there is a rapid and considerable reduction in pain and stiffness and an improvement in the functional state. In addition, the pleiotropic effects of the drug make it possible not only to effectively reduce weight, but also perhaps to improve the course of MS-associated conditions by the observed corrections of metabolic disturbances.

osteoarthritis, metabolic syndrome, treatment, diacerein

1. Allen KD, Choong PF, Davis AM, et al. OA: Models for appropriate care across the disease continuum. Best Pract Res Clin Rheumatol.2016 Jun;30(3):503-35. doi: 10.1016/j.berh.2016.09.003

2. World Health Organization: Obesity and overweight. Fact Sheet No.311. accessed on November 20, 2012. 2013. Mar. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/

3. World Health Organization. Obesity: Preventing And Managing The Global Epidemic. Geneva: WHO; 1997.

4. Blagojevic M, Jinks C, Jeffery A, Jordan KP. Risk factors for onset of osteoarthritis of the knee in older adults: A systematic review and meta-analysis. Osteoarthritis Cartilage. 2010 Jan;18(1):24-33. doi: 10.1016/J.Joca.2009.08.010

5. Fu Y, Griffin TM. Obesity, osteoarthritis and aging: The biomechanical links. Mechanobiology of obesity and related diseases. Springer International Publishing; 2015. P. 181-201.

6. Kashevarova NG, Alekseeva LI, Taskina EA, Smirnov AV. The leading factors in the progression of osteoarthritis of knee joints. The effect of symptomatic delayed-action drugs on the course of the disease (a 5-year prospective study). Farmateka. 2017;7(340):40-5 (In Russ.).

7. Jiang L, Tian W, Wang Y, et al. Body mass index and susceptibility to knee osteoarthritis: a systematic review and meta-analysi. Joint Bone Spine. 2012 May;79(3):291-7. doi: 10.1016/j.jbspin.2011.05.015

8. Wang Y, Simpson JA, Wluka AE, et al. Relationship between body adiposity measures and risk of primary knee and hip replacement for osteoarthritis: a prospective cohort study. Arthritis Res Ther. 2009;11(2):R31. doi: 10.1186/ar2636

9. McNulty AL, Miller MR, O'Connor SK, Guilak F. The effects of adipokines on cartilage and meniscus catabolism. Connect Tissue Res. 2011;52(6):523-33. doi: 10.3109/03008207.2011.597902

10. Hanefeld M, Schaper F, Ceriello A. Geschichte Und Definition(En) Des Metabolischen Syndroms. Internist. 2007;48:117-25. doi: 10.1007/s00108-006-1786-5

11. Diagnosis and treatment of metabolic syndrome. In: Sbornik natsional'nykh klinicheskikh rekomendatsii [Collection of National Clinical Recommendations]. Moscow: Silitseya-Poligraf; 2009. P. 106-43 (In Russ.).

12. Wang H, Cheng Y, Shao D, et аl. Metabolic syndrome increases the risk for knee osteoarthritis: A meta-analysis. Evid Based Complement Alternat Med. 2016;2016:7242478. doi: 10.1155/2016/7242478

13. Shin D. Association between metabolic syndrome, radiographic knee osteoarthritis, and intensity of knee pain: Results of a national survey. J Clin Endocrinol Metab. 2014 Sep;99(9):3177-83. doi: 10.1210/jc.2014-1043

14. Velasquez MT, Katz JD. Osteoarthritis: Another component of metabolic syndrome? Metab Syndr Relat Disord. 2010 Aug;8(4):295-305. doi: 10.1089/met.2009.0110

15. Yoshimura N, Muraki S, Oka H, et al. Accumulation of metabolic risk factors such as overweight, hypertension, dyslipidaemia, and impaired glucose tolerance raises the risk of occurrence and progression of knee osteoarthritis: A 3-year follow-up of the road study. Osteoarthritis Cartilage. 2012 Nov;20 (11):1217-26. doi: 10.1016/j.joca.2012.06.006

16. Yoshimura N, Muraki S, Oka H, et al. Association of knee osteoarthritis with the accumulation of metabolic risk factors such as overweight, hypertension, dyslipidemia, and impaired glucose tolerance in japanese men and women: The road study. J Rheumatol. 2011;38(5):921-30. doi: 10.3899/Jrheum.100569

17. Abourazzak F, Talbi S, Lazrak F, et al. Does metabolic syndrome or its individual components affect pain and function in knee osteoarthritis women? Curr Rheumatol Rev. 2015 May 21. doi: 10.2174/1573397111666150522093337

18. Chadha R. Revealed aspect of metabolic osteoarthritis. J Orthop. 2016 Jul 9;13(4):347-51. doi: 10.1016/j.jor.2016.06.029.eCollection 2016 Dec.

19. Farnaghi S, Crawford R, Xiao Y, Prasadam I. Cholesterol metabolism in pathogenesis of osteoarthritis disease. Int J Rheum Dis. 2017 Feb;20(2):131-40. doi: 10.1111/1756-185X.13061

20. Martel-Pelletier J, Pelletier JP. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis.2010 Apr;2(2):95-104. doi: 10.1177/1759720X09359104

21. Steinecker-Frohnwieser B, Kaltenegger H, Weigl L, et al. Pharmacological treatment with diacerein combined with mechanical stimulation affects the expression of growth factors in human chondrocytes. Biochem Biophys Rep. 2017 Jul 1;11:154-60. doi: 10.1016/j.bbrep.2017.06.006

22. Sun H, Luo G, Chen D, Xiang Z. A comprehensive and system review for the pharmacological mechanism of action of rhein, an active anthraquinone ingredient. Front Pharmacol. 2016 Aug 17;7:247. doi: 10.3389/fphar.2016.00247. eCollection 2016.

23. Zhou YX, Xia W, Yue W, et al. Rhein: A review of pharmacological activities. Evid Based Complement Alternat Med. 2015;2015:578107. doi: 10.1155/2015/578107

24. Naumov AV, Khovasova NO. Recommended osteoarthritis therapy: new solutions to old problems. Russkii Meditsinskii Zhurnal. 2016;24(3):197-202 (In Russ.).

25. Jatwa R, Kar A.Anti-inflammatory and anti-peroxidative roles of diacerein are possibly mediated through an alteration in thyroid functions in animal model of inflammation. Fundament Clin Pharmacol. 2009;23(4):465-71. doi: 10.1111/j.1472-8206.2009.00685.x

26. Alekseeva LI, Kashevarova NG, Taskina EA, et al. Efficacy and safety of diacerein in patients with knee osteoarthritis. Sovremennaya Revmatologiya = Modern Rheumatology Journal.2017;11(3):50-7 (In Russ.). doi: 10/14412/1996-7012-2017-3-50-57

27. Sharapova EP, Kashevarova NG, Zaitseva EM, et al. Evaluation of the efficacy and safety of diacerein in patients with osteoarthrosis of the hip joints. Meditsinskii Sovet. 2017;(1s):84-9 (In Russ.).

28. Karateev AE, Alekseeva LI, Tsurgan AV, Gontarenko NV. Evaluation of the efficacy and safety of complex therapy of musculoskeletal pain with the use of Diacerein (according to the ROCADA study – a retrospective evaluation of the clinical aspects of the use of diaphlexa in osteoarthritis). Nevrologiya i Revmatologiya. Prilozhenie k zhurnalu Consilium Medicum. 2016;(2):26-32 (In Russ.).

29. Pavelka K, Bruyere O, Cooper C, et al. Diacerein: benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCEO. Drugs Aging. 2016;33(2):75-85. doi: 10.1007/s40266-016-0347-4

30. Li H, George DM, Jaarsma RL, Mao X. Metabolic syndrome and components exacerbate osteoarthritis symptoms of pain, depression and reduced knee function. Ann Transl Med. 2016 Apr;4(7):133. doi: 10.21037/atm.2016.03.48

31. Tootsi K, Mаrtson A, Kals J, et al. Metabolic factors and oxidative stress in osteoarthritis: a case-control study. Scand J Clin Lab Invest. 2017 Jul 24:1-7. doi: 10.1080/00365513.2017.1354255

32. Yasuda E, Nakamura R, Matsugi R, et al. Association between the severity of symptomatic knee osteoarthritis and cumulative metabolic factors. Aging Clin Exp Res. 2017 Jul 31. doi: 10.1007/s40520-017-0808-6

33. Baudart P, Louati K, Marcelli C, et al. Association between osteoarthritis and dyslipidaemia: a systematic literature review and meta-analysis. RMD Open. 2017;3:e000442. doi: 10.1136/ rmdopen-2017-000442

34. Du H, Shao J, Gu P, et al. Improvement of glucose tolerance by rhein with restored early-phase insulin secretion in db/db mice. J Endocrinol Invest 2012;35:607-12. doi: 10.1007/BF03345796

35. Liu J, Chen Z, Zhang Y, et al. Rhein protects pancreatic B-cells from dynamin-related protein-1-mediated mitochondrial fission and cell apoptosis under hyperglycemia. Diabetes. 2013;62:3927-393. doi: 10.2337/db13-0251

36. Tobar N, Oliveira AG, Guadagnini D, et al. Diacerhein improves glucose tolerance and insulin sensitivity in mice on a high-fat diet. Endocrinology. 2011;152:4080-93. doi: 10.1210/en.2011-0249

37. Malaguti C, Vilella CA, Vieira KP, et al. Diacerhein downregulate proinflammatory cytokines expression and decrease the autoimmune diabetes frequency in nonobese diabetic (NOD) mice. Int Immunopharmacol.2008;8:782-91. doi: 10.1016/j.intimp.2008.01.020

38. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860-7. doi: 10.1038/nature05485

39. Ramos-Zavala MG, Gonzalez-Ortiz M, Martinez-Abundis E, et al. Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trial. Diabetes Care.2011 Jul;34(7):1591-4. doi: 10.2337/dc11-0357

40. Villar MM, Martinez-Abundis E, Preciado-Mаrquez RO, Gonzalez-Ortiz M. Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. Arch Endocrinol Metab. 2017 Mar-Apr;61(2):188-92. doi: 10.1590/2359-3997000000242

41. Cardoso CRL, Leite NC, Carlos FO, et al. Efficacy and safety of diacerein in patients with inadequately controlled type 2 diabetes: A randomized controlled trial. Diabetes Care. 2017 Aug;dc170374. doi: 10.2337/dc17-0374

42. Sheng X, Wang M, Lu M, et al. Rhein ameliorates fatty liver disease through negative energy balance, hepatic lipogenic regulation, and immunomodulation in diet-induced obese mice. Am J Physiol Endocrinol Metab. 2011;300:886-93. doi: 10.1152/ajpendo.00332.2010

43. Lin YJ, Hu G, Li KJ, et al. The protection of rhein lysinate to liver in diabetic mice induced by high-fat diet and streptozotocin. Arch Pharm Res. 2015;38:885-92. doi: 10.1007/s12272-014-0423-4

44. Guo MZ, Li XS, Xu HR, et al. Rhein inhibits liver fibrosis induced by carbon tetrachloride in rats. Acta Pharmacol Sinica. 2002;23(8):739-44.